ENTITY
Ascletis Pharma

Ascletis Pharma (1672 HK)

112
Analysis
Health Care • China
Ascletis Pharma is a fully integrated biotechnology company focused on the research, development, production, marketing, and sale of innovative pharmaceutical products. The company's marketed products include Ritonavir tablets, GANOVO®, and ASCLEVIR® for Hepatitis C, and it has a robust pipeline primarily in metabolic diseases, viral diseases, and oncology. Ascletis Pharma is headquartered in Hangzhou, China, and was founded in 2011.
more
bearish•Babytree
•19 Nov 2018 11:47

Last Week in GER Research: Babytree, NTT, Tongcheng, IDreamSky, Fosun, Sinochem, and Mogu

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team. This week we highlight the latest on...

Logo
781 Views
Share
bearish•Softbank Group
•12 Nov 2018 06:05

Last Week in GER Research: Softbank, Haidilao, Tongcheng-Elong, Ctrip and 360 Finance

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.  This week we update on Softbank Group (9984...

Logo
467 Views
Share
bearish•Softbank Group
•05 Nov 2018 06:03

Last Week in GER Research: Softbank, Babytree, Tencent Music, MYOB, Yancoal, Spotify Warning & More!

Below is a recap of the key IPO and event-driven research produced by the Global Equity Research team.  Last week, Arun initiated IPO coverage...

Logo
437 Views
Share
•01 Nov 2018 14:21

Innovent Biologics (信达生物) Post IPO: Hit Our TP, What's Next?

Innovent Biologics was priced at the high end and it started trading yesterday (November 1st). It traded up by 18.5% on the first day and 8% on the...

Logo
869 Views
Share
•31 Oct 2018 16:39

Innovent Biologics IPO First-Day: Take Money off the Table

Despite a recent spell of lacklustre early-stage biotech flotations that have slumped post-IPO, Innovent Biologics Inc (1801 HK)'s shares popped...

Logo
721 Views
Share
x